Meet Our Team.

Leaders in drug discovery & innovation.

Meet Our Team.

Leaders in drug discovery & innovation.

Alex Belser, PhD

Alex Belser, PhD, is a clinical scientist, psychologist, and psychedelic researcher formerly at NYU and Yale University. His book, EMBARK Psychedelic Therapy for Depression (Oxford University Press), co-authored with Dr. Bill Brennan, offers a clinical guide to working with psychedelic medicines. He has taught in over a dozen psychedelic training programs about psilocybin, MDMA, ketamine, and DMT therapies. Dr. Belser co-founded the NYU Psychedelic Research Group in 2006 and a non-profit psychedelic center called Nautilus Sanctuary. He served as the Chief Clinical Officer of Cybin, leading clinical teams in the US and Europe. His work has been featured in the media, with coverage in the New York Times, the Atlantic, The Guardian, Forbes, Rolling Stone, NPR, and in Michael Pollan's book, How to Change Your Mind. He studied at Georgetown, Cambridge, Columbia, NYU, and Yale. Belser has taught at Harvard Medical School, Yale University, UCLA, the Karolinska Institute, the University of Washington, NYU, CUNY, and the New York Academy of Medicine.

Bill Brennan, PhD

A leading consultant and expert in psychedelic clinical trials, Bill has built a proven track record in designing and overseeing clinical programs to advance novel therapies.

His expertise brings critical regulatory and operational insights to the team, ensuring best practices in trial design and execution.

Bill’s vision and operational excellence accelerate the development and approval of groundbreaking psychedelic treatments.

Michael Palfreyman, PhD

Michael G. Palfreyman is a seasoned leader specializing in drug discovery and development, translational R&D and early clinical proof of concept for the biotechnology and pharmaceutical industries. Dr. Palfreyman has over 40 years’ experience in leadership roles, including vice president, chairman of the board, chief scientific officer, senior scientific advisor, R&D diligence, translational R&D, scientific advising, program management, and product development. He is currently Chairman and CEO for C-Click Life Sciences, Inc. and has been elected as a non-executive director at N4Pharma. Companies and clients include Cybin, Inc., Marion Merrell Dow (Sanofi Aventis), Scriptgen (Anadys) Pharmaceuticals, EnVivo (Forum) Pharmaceuticals, Amakem Therapeutics, and Aminex Therapeutics, and more. Dr. Palfreyman has been an invited speaker and chairperson for several international and national conferences, is co-inventor on 53 issued US patents, 12 pending patents and co-author of over 150 scientific articles and book chapters. View list of publications, citations, and patents.

Tommy MacLane

Tommy MacLane is a former professional baseball player for the Boston Red Sox who transitioned from the field to the world of finance. With over a decade of experience in financial M&A advisory, he has guided clients through complex transactions across diverse industries as a Sr C Level M&A Advisor for a publicly traded company and an international bank. Currently, Mr. MacLane is a Sr. Advisor at Endeavor Advisory Group, a leading investment bank, Tommy specializes in capital raising for M&A. deals > $100M. His unique background blends the discipline of professional sports with the strategic insight of high-stakes dealmaking.

Notice

Confidential and Proprietary

© 2025 MindMerge Advisors

All rights reserved

Notice

Confidential and Proprietary

© 2025 MindMerge Advisors

All rights reserved

Notice

Confidential and Proprietary

© 2025 MindMerge Advisors

All rights reserved